Showing 1 - 10 of 34 records.

ACNS0821: Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

  • Conditions: Cancer - Brain and Spinal Tumors, Neurology
  • Gender: Female, Male

This randomized phase II trial is studying how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or CNS primitive neuroectodermal tumors. ...More

ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas

  • Conditions: Cancer - Brain and Spinal Tumors
  • Gender: Female, Male

This randomized phase II/III trial is studying vorinostat, temozolomide, or bevacizumab to see how well they work compared with each other when given together with radiation therapy followed by bevacizumab and temozolomide in treating young patients with newly diagnosed high-grade glioma. ...More

ACNS1022: A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

  • Conditions: Cancer - Brain and Spinal Tumors
  • Gender: Female, Male

This randomized phase II trial studies low-dose lenalidomide to see how well it works in treating younger patients with recurrent, refractory or progressive juvenile pilocytic astrocytomas or optic nerve pathway gliomas. ...More

ACNS1123: A Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors.

  • Conditions: Cancer - Brain and Spinal Tumors

This phase II trial studies how well chemotherapy and radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors. ...More

ADVL0815: Phase I Study Pazopanib Single Agent for Solid Tumor

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Liver Tumors, Neurology
  • Gender: Female, Male

This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. ...More

ADVL0816: A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/ Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Leukemia and Lymphoma
  • Gender: Female, Male

Primary Estimate the maximum-tolerated dose and/or recommended phase II dose of obatoclax mesylate in combination with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in pediatric patients with refractory solid tumors Define and describe the toxicities of ob ...More

ADVL1011: A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Hemangioma and Vascular Malformation, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.  ...More

ADVL1013: A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors
  • Gender: Female, Male

This phase I trial is studying the side effects, best way to give, and best dose of MK2206 in treating patients with recurrent or refractory solid tumors or leukemia. ...More

ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...More

ADVL1115: A Phase I Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors.

  • Conditions: Cancer - Brain and Spinal Tumors
  • Gender: Female, Male

This phase I trial studies the side effects and the best dose of trebananib in treating patients with relapsed or refractory solid tumors, including central nervous system tumors. ...More

Contact Us

hospital

Adult Participants or Parents of Participants:

Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at clinicalstudies@cchmc.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.

Sponsors and Investigators:

The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.